Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
ID: 345341Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345341

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-061.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the R21 Exploratory/Developmental Research Grant aimed at optimizing HIV prevention and care continuum outcomes. This funding opportunity encourages innovative research proposals that enhance understanding of the HIV prevention and care continuum, addressing barriers to access and effectiveness, with a focus on socio-economic disparities, treatment adherence, and HIV-related stigma. The total funding amount is capped at $275,000 over a two-year period, with applications due by January 9, 2026. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-061.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-061-Full-Announcement.html
    PAR-23-061.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting applications for the R21 Exploratory/Developmental Research Grant aimed at optimizing HIV prevention and care outcomes. This funding opportunity encourages innovative research proposals that enhance understanding of the HIV prevention and care continuum, addressing key barriers to access and effectiveness. The grant focuses on diverse approaches to HIV testing, treatment adherence, and retention in care, highlighting the importance of community engagement and multi-level interventions. Key objectives include addressing socio-economic disparities, improving adherence to treatment, and understanding the factors influencing HIV-related stigma. Various application types are permitted, and projects should aim for practical implications and scalability. The total budget is capped at $275,000 over two years, with multiple submission deadlines. This initiative aligns with national and global health goals, notably the U.S. National HIV/AIDS Strategy, which aims for significant reductions in HIV transmission through comprehensive care and prevention strategies. Proposals are encouraged from a wide range of organizations, including minority-serving institutions, emphasizing collaborative and innovative approaches to HIV research.
    Similar Opportunities
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)" under the National Institute of Mental Health (NIMH). This initiative aims to support innovative research focused on optimizing HIV prevention and care, emphasizing the understanding of behavioral and social science factors that influence the HIV continuum, including intervention efficacy trials and implementation science studies. The program is critical for advancing national efforts to address HIV effectively, promoting community engagement and multidisciplinary collaboration to achieve equitable health outcomes for diverse populations. Interested applicants can find more information and application details at the provided link, with a submission deadline of January 9, 2026, and no cost-sharing or matching requirements.
    Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)." This initiative aims to support formative research and pilot-testing of interventions designed to enhance HIV prevention and treatment outcomes, particularly focusing on innovative strategies that address mental health, social determinants, and structural factors affecting HIV care. The funding opportunity is crucial for developing effective HIV testing and treatment linkage strategies, ultimately contributing to national goals in HIV management and reducing health disparities among affected populations. Eligible applicants can receive direct costs up to $225,000 per year for a project duration not exceeding three years, with applications due by January 9, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-060.html.
    Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity (PA-21-205) aimed at the development and testing of innovative interventions to enhance HIV prevention, treatment, and program implementation for individuals who use drugs. This R34 grant focuses on formative research and pilot studies that assess the feasibility, safety, and acceptability of various interventions, including behavioral, social, and structural approaches, particularly integrating substance use considerations into HIV care. The initiative is crucial in addressing the ongoing challenges of the HIV epidemic among populations significantly impacted by substance use, with projects expected to enhance HIV testing, preventive services, and treatment adherence. Interested applicants can apply for grants with a ceiling of $225,000, and the application deadline is January 7, 2025. For further information, contact the NIH OER Webmaster at grantsinfo@nih.gov or visit the funding announcement at http://grants.nih.gov/grants/guide/pa-files/PA-21-205.html.
    Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for pilot studies focused on the biological, behavioral, and social mechanisms contributing to HIV pathogenesis, specifically under the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This funding opportunity aims to support innovative basic and translational research aligned with NIH HIV/AIDS priorities, addressing critical issues such as HIV comorbidities and health-impeding social determinants. Eligible applicants include a diverse range of institutions, including educational and nonprofit organizations, with funding available up to $275,000 over a two-year period. The application period opens on April 8, 2024, with a submission deadline of January 7, 2025; for further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at exploring innovative HIV cure strategies at the initiation of combination antiretroviral therapy (cART). This initiative seeks to identify and develop interventions that can be applied at the start of cART or following treatment interruptions, with the ultimate goal of achieving sustained treatment-free remission. The funding, available for up to two years with a maximum budget of $275,000, is open to a diverse range of eligible applicants, including higher education institutions, non-profits, and for-profit entities. Interested parties can find more information and application guidelines at the NIH grants website, with a submission deadline set for September 7, 2026.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer," aimed at supporting pilot and exploratory research. This initiative seeks to investigate the combined effects of cancer and HIV stigma on health outcomes for individuals living with HIV who are also diagnosed with cancer, with a focus on developing stigma reduction interventions and promoting research in regions with high burdens of both diseases. The grant, which has a maximum budget of $275,000 for a duration of up to two years, encourages applications from a diverse range of eligible entities, including educational institutions and community organizations. Interested applicants should note that the application period opens on November 13, 2024, and the submission deadline is December 10, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link provided in the announcement.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research in integrated care models for HIV/AIDS and substance use disorders. The initiative seeks to improve health outcomes and enhance care coordination for individuals at heightened risk by addressing service delivery gaps through collaborative and evidence-based practices. This grant, with a funding ceiling of $450,000 over three years, is open to a diverse range of eligible applicants, including higher education institutions and community-based organizations, with applications due by March 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-020.html.